header-logo
GettyImages-758308167-hero
Biostatistics
Paul Auer

Paul Auer, PhD

Cancer Center Scholar; Director, Biostatistics Shared Resource, Cancer Center; Professor, Data Science Institute, Biostatistics

Locations

  • Biostatistics, Center for Cancer Discovery, N1164

Contact Information

Education

PhD, Purdue University, West Lafayette, IN, 2010
MPS, Cornell University, Ithaca, NY, 2003
BA, SUNY Geneseo, Geneseo, NY, 2001

Biography

Research Experience:
Statistical Genetics; GWAS, Complex Trait Genetics, Rare-Variants, Whole-Genome Sequencing

Research Interests

Dr. Auer is a statistical geneticist with expertise in the analysis of whole genome sequencing and multi-omic data. He has collaborated on several large-scale projects focused on understanding the genetic basis of complex diseases such as stroke, heart disease, and cancer. He collaborates with faculty in the Department of Physiology, the Center of International Blood & Marrow Transplant Research, and the MCW Cancer Center. His current research interests include multi-omic data analysis for predicting phenotypic states and disease outcomes and developing methods to detect clonal mosaicism.

Publications

  • Deep learning on genome-wide association studies to predict the patient-specific risk of radiation-induced erectile dysfunction.

    (Oh JH, Auer P, Hall W, Rosenstein BS, Deasy JO, Kerns S.) Radiother Oncol. 2026 Jun;219:111531 PMID: 41967608 PMCID: PMC13135471 SCOPUS ID: 2-s2.0-105035768838 04/13/2026

  • Co-occurring clonal hematopoiesis exhibits strong selection and high leukemia risk.

    (Barnao KM, Hubbard AK, Chan ICC, Zhou W, Jakubek YA, Genovese G, Wong WSW, Kelly RL, Young CD, Brown DW, Huang WY, Freedman ND, Jones K, Hutchinson A, Hicks B, Tran D, Arnett D, Barnes KC, Bis JC, Boerwinkle E, Brody JA, Carson AP, Chasman DI, Cho MH, Desai P, Doyle MF, Fornage M, Guo X, Heard-Costa N, Irvin MR, Johnson AD, Kardia SLR, Kooperberg C, Levy D, Lewis JP, Li Y, Loos RJF, Mack TM, Mathias RA, Mitchell BD, North KE, Pankratz N, Peyser PA, Preuss MH, Psaty BM, Raffield LM, Redline S, Rich SS, Rotter JI, Silverman EK, Smith AV, Smith JA, Stilp A, Cao Y, Scheet P, Reiner AP, Bick AG, Chanock SJ, Auer PL, Bolton KL, Machiela MJ.) Nat Commun. 2026 May 21 PMID: 42168198 05/22/2026

  • Whole Blood Transcriptomic Analysis of Sickle Cell Trait.

    (Johnson M, Cai Y, Vasconcelos AG, Orchard P, Auer PL, Lettre G, Wen J, Franceschini N, Kooperberg C, Sun W, Hsu L, Raffield LM, Reiner AP.) Eur J Haematol. 2026 May;116(5):535-544 PMID: 41528117 PMCID: PMC13050677 01/13/2026

  • Mosaic Loss of Y chromosome associates with lung function, emphysema and epigenetic aging.

    (Saw WY, Kim K, Huang Y, Yun JH, Ma X, Bacon J, Pershad Y, Levy D, O'Connor GT, Boerwinkle E, Barr RG, Rich SS, Rotter JI, Carson AP, Raffield LM, Gharib SA, Bartz TM, Psaty BM, Sofer T, North KE, Kaplan R, Oelsner EC, Manichaikul A, Bick AG, Scheet P, Reiner AP, NHLBI Trans-Omics for Precision Medicine Consortium , Jakubek YA, Auer PL, Cho MH, DeMeo DL.) Am J Respir Crit Care Med. 2026 Mar 19 PMID: 42085243 05/05/2026

  • Alterations of Plasma Metabolites Associated with Sickle Cell Trait.

    (Cai Y, Surapaneni A, Vasconcelos AG, Johnson M, Hsu L, Sun W, Kooperberg C, Yu B, Yeo WJ, Auer PL, Grams ME, Franceschini N, Raffield LM, Reiner AP.) Clin J Am Soc Nephrol. 2026 Feb 27 PMID: 41758580 02/27/2026

  • Fine Mapping of MHC Region Identifies Novel Susceptibility Loci in Multiple Myeloma When Comparing With Its Precursor Monoclonal Gammopathy of Unknown Significance.

    (Arsang-Jang S, Massat B, Pareek G, Han J, Thapa B, Patek V, Nader Z, Auer PL, Zimmerman MT, Urrutia R, Hari P, D'Souza A, Dhakal B, Janz S, Dong J.) HLA. 2026 Feb;107(2):e70589 PMID: 41685425 PMCID: PMC12902906 SCOPUS ID: 2-s2.0-105029925738 02/13/2026

  • cellSTAAR: incorporating single-cell-sequencing-based functional data to boost power in rare variant association testing of noncoding regions.

    (Van Buren E, Zhang Y, Li X, Selvaraj MS, Li Z, Zhou H, Palmer ND, Arnett DK, Blangero J, Boerwinkle E, Cade BE, Carlson JC, Carson AP, Chen YI, Curran J, Duggirala R, Fornage M, Franceschini N, Graff M, Gu C, Guo X, He J, Heard-Cosa N, Hou L, Hung YJ, Kalyani RR, Kardia SLR, Kenny E, Kooperberg C, Kral BG, Lange L, Levy D, Li C, Liu S, Lloyd-Jones D, Loos RJF, Manichaikul AW, Martin LW, Mathias R, Minster RL, Mitchell BD, Mychaleckyj JC, Naseri T, North K, O'Connell J, Perry JA, Peyser PA, Psaty BM, Raffield LM, Vasan RS, Redline S, Reiner AP, Rich SS, Smith JA, Spitzer B, Tang H, Taylor KD, Tracy R, Viali S, Yanek L, Zhao W, NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium, Rotter JI, Peloso GM, Natarajan P, Lin X.) Nat Methods. 2026 Feb;23(2):338-349 PMID: 41476111 SCOPUS ID: 2-s2.0-105027787046 01/01/2026

  • Large-scale meta-analysis and precision functional assays identify FANCM regions in which PTVs confer different risks for ER-negative and triple-negative breast cancer.

    (Billaud A, Figlioli G, Mooser C, Casamassima I, Azzoni V, Srivatsa J, Colombo M, Caleca L, Ahearn TU, Andrulis IL, Antoniou AC, Beckmann MW, Behrens S, Bermisheva M, Bogdanova NV, Bolla MK, Bonanni B, Brüning T, Camp NJ, Campbell A, Castelao JE, Cessna MH, Chang-Claude J, NBCS Collaborators, Czene K, Dennis J, Devilee P, Dörk T, Dunning AM, Eriksson M, Evans DG, Fasching PA, Figueroa JD, Gabrielson M, Gago-Dominguez M, González-Neira A, Guénel P, Hadjisavvas A, Hahnen E, Hamann U, Hillemanns P, Hollestelle A, Hooning MJ, Hoppe R, Howell A, kConFab Investigators, Jakubowska A, Kristensen VN, Lubiński J, Lush M, Manoukian S, Mavroudis D, Milne RL, Mulligan AM, Newman WG, Obi N, Panayiotidis MI, Pita G, Rashid MU, Rhenius V, Saloustros E, Sawyer EJ, Schmutzler RK, Shah M, Southey MC, Spurdle AB, Tomlinson I, Truong T, Wang Q, Wendt C, Auer PL, Boddicker NJ, Bodelon C, Burnside ES, Chen F, Couch FJ, Domchek SM, Eliassen HA, Haiman C, Hodge JM, Hu C, Huang H, Lindstrom S, Martinez ME, Nathanson KL, Neuhausen SL, O'Brien KM, Olson JE, Palmer JR, Patel AV, Ruddy KJ, Sandler DP, Teras LR, Weinberg CR, Weitzel JN, Winham SJ, Yadav S, Yao S, Zirpoli G, Janatova M, Kleibl Z, Kleiblova P, Soukupova J, CZECANCA consortium, Zhao Q, Devereux L, James PA, Campbell IG, Nguyen-Dumont T, Dowty JG, Andrieu N, Lesueur F, Stoppa-Lyonnet D, GENESIS, Hoya M, Radice P, Sørensen CS, Peterlongo P.) Breast. 2026 Feb;85:104619 PMID: 41223770 PMCID: PMC12657754 11/13/2025

  • Autoimmune HLA alleles and neoantigens predict myelodysplastic syndrome outcomes after allogeneic HSCT: A CIBMTR analysis.

    (Sears T, Kurzrock R, Zhang T, Dong J, Spellman SR, Goodman AM, Bolon YT, Chen Z, Auer P, Saber W, Carter H.) iScience. 2026 Jan 16;29(1):114326 PMID: 41550735 PMCID: PMC12804621 SCOPUS ID: 2-s2.0-105027049401 01/19/2026

  • Novel Genomic Biomarkers Improve Post-Hematopoietic Cell Transplantation Relapse Risk Stratification for Patients With Myelodysplastic Syndromes.

    (Zhang T, Auer PL, Dong J, Chen Z, Spellman SR, Saber W, Bolon YT.) JCO Precis Oncol. 2026 Jan;10:e2500140 PMID: 41576307 PMCID: PMC12932076 SCOPUS ID: 2-s2.0-105035092780 01/23/2026

  • Integrating whole genome and transcriptome sequencing to characterize the genetic architecture of isoform variation.

    (Liu C, Joehanes R, Ma J, Xie J, Yang J, Wang M, Huan T, Hwang SJ, Wen J, Sun Q, Demirkale CY, Heard-Costa NL, Orchard P, Carson AP, Haessler JW, Raffield LM, Reiner AP, Franceschini N, Auer PL, Kooperberg C, Li Y, O'Connor G, Murabito JM, Munson P, Levy D.) Nat Commun. 2025 Nov 22;16(1):10615 PMID: 41274869 PMCID: PMC12660940 11/23/2025

  • Genetic determinants and genomic consequences of non-leukemogenic somatic point mutations.

    (Weinstock JS, Chaudhry SA, Ioannou M, Viskadourou M, Reventun P, Jakubek YA, Liggett LA, Laurie C, Broome JG, Khan A, Taylor KD, Guo X, Peyser PA, Boerwinkle E, Chami N, Kenny EE, Loos RJ, Psaty BM, Tracy RP, Brody JA, Yun JH, Cho MH, Vasan RS, Kardia SL, Smith JA, Raffield LM, Bidulescu A, O'Brien EC, de Andrade M, Rotter JI, Rich SS, Tracy RP, Chen YI, Gu CC, Hsiung CA, Kooperberg C, Haring B, Nassir R, Mathias R, Reiner A, Sankaran VG, Lowenstein CJ, Blackwell TW, Abecasis GR, Smith AV, Kang HM, Natarajan P, Jaiswal S, Bick A, Post WS, Scheet P, Auer P, Karantanos T, Battle A, Arvanitis M.) Nat Commun. 2025 Oct 16;16(1):9194 PMID: 41102182 PMCID: PMC12532822 10/17/2025

Publications of Paul L. Auer PhD from the Faculty Collaboration Database

© 2026 Medical College of Wisconsin.  All rights reserved.  | Terms and Privacy | Web Accessibility Statement

Non-Discrimination, Anti-Harassment, and Legal Compliance Statement
The Medical College of Wisconsin (MCW) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, military status, or other legally protected classification. MCW maintains full compliance with all applicable federal, state, and local laws and regulations in pursuit of our missions. Consistent with federal guidance, we affirm our commitment to individual merit, fairness, and equal treatment in all aspects of academic and institutional decision-making.

MCW's policies, federal and state laws, and regulations prohibit unlawful discrimination and harassment. Employees, learners, students, applicants, or other members of the MCW community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic.